Researchers recently developed innovative boron-doped aggregation-induced emission (AIE) nanomaterials to improve dual-modality tumor imaging. These B@AIE NPs integrate near-infrared II (NIR-II) fluorescence with magnetic resonance (MR) contrast capabilities. Consequently, this metal-free nanoprobe addresses many limitations of single-modality diagnostic tools in oncology.

The Science Behind Dual-Modality Tumor Imaging

The study utilized a facile one-pot solvothermal method to synthesize the B@AIE NPs. These particles feature a uniform core-shell structure and exhibit strong NIR-II fluorescence at 984 nm. Furthermore, the boron doping provides remarkable T1-weighted MR contrast. The longitudinal relaxivity (r1) reached 6.12 mM⁻¹ s⁻¹, which is significantly high for metal-free materials. This emission stems from restricted intramolecular motion within the aggregated nanoparticles. Additionally, these nanomaterials accumulate effectively in tumors through the enhanced permeability and retention (EPR) effect.

In vitro assessments confirmed the excellent biocompatibility of these nanoparticles. Specifically, the probes primarily localized within lysosomes following efficient cellular uptake. Moreover, in vivo experiments using HeLa tumor-bearing mice demonstrated superior tumor accumulation. This enabled high-contrast visualization across both imaging modalities simultaneously. Therefore, these findings suggest that B@AIE NPs represent a promising tool for precise clinical diagnosis.

Frequently Asked Questions

What are the main benefits of B@AIE NPs?

B@AIE NPs offer high-contrast NIR-II fluorescence and efficient MR imaging. They provide deep tissue penetration and high spatial resolution without the toxicity risks often associated with heavy metals.

How do these nanoparticles target tumors?

The nanoparticles utilize the enhanced permeability and retention (EPR) effect to accumulate naturally in tumor tissues. This mechanism allows for precise localization and high-contrast imaging in various oncological applications.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional recommendation. Healthcare professionals should consult the original research and adhere to the latest local and national guidelines for clinical practice.

References

Kou X et al. Boron-Doped AIE Nanomaterials With NIR-II Emission for FL/MR Dual-Modality Tumor Imaging. Small. 2026 May 03. doi: 10.1002/smll.73637. PMID: 42070299.

Li Z et al. Inorganic and hybrid nanomaterials for NIR-II fluorescence imaging-guided therapy of Glioblastoma and perspectives. Theranostics. 2025; 15(12):5616-5665.

Shao J et al. Boron difluoride formazanate dye for high-efficiency NIR-Ⅱ fluorescence imaging-guided cancer photothermal therapy. Chemical Engineering Journal. 2022; 433:133578.